Article

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Verify the Efficacy and Safety of Ansofaxine (LY03005) for Major Depressive Disorder

2022-10-25

Abstract excerpt

<title>Abstract</title> <p>Major depressive disorder (MDD) is the most prevalent form of depression and is becoming a great challenge for public health and medical practice. Although first-line antidepressants offer therapeutic benefit, about 35% of depressed patients are not adequately treated, creating a substantial unmet medical need. A multicenter, double-blind, randomized, placebo-controlled phase 3 clinical...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2741ba45-79e2-5639-a024-6dcd4d1dc57b
DOI: 10.21203/rs.3.rs-2178948/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Verify the Efficacy and Safety of Ansofaxine (LY03005) for Major Depressive DisorderDOI 10.21203/rs.3.rs-2178948/v1Read

Tolerability and Efficacy of Vortioxetine Versus SSRIs in Elderly With Major Depression. Study Protocol of the VESPA Study: A Pragmatic, Multicentre, Open-Label, Parallel-Group, Superiority, Randomized TrialSemantic proximity Read

Anti-Depression a Systematic Review of Analytical methods in PharmaceuticalsSemantic proximity Read

Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extensionSemantic proximity Read

Side effect profile and comparative tolerability of newer generation antidepressants in the acute treatment of major depressive disorder in children and adolescents: protocol for a systematic review and network meta-analysisSemantic proximity Read

Psychedelic Therapy: A Primer for Primary Care Clinicians—MescalineSemantic proximity Read

International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets.Semantic proximity Read

[Personalized treatment of depression phenotypes: role of trazodone in depression with insomnia].Semantic proximity Read

Agomelatine: An astounding sui generis antidepressant?Semantic proximity Read

Do no harm: a paradigm shift in the unchecked use of antidepressants.Semantic proximity Read

Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)Semantic proximity Read

Real-world patient characteristics, treatment patterns, efficacy and safety of intramuscular ketamine treatment: a retrospective cohort studySemantic proximity Read

A novel NR3C2 polymorphism and the increased thyroid-stimulating hormone concentration are associated with venlafaxine treatment outcome in Chinese Han MDD patients.Semantic proximity Read